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Abstract 
Background: Niemann‑Pick disease type C (NP‑C) is a rare, autosomal recessive neurodegenerative disease caused 
by mutations in either the NPC1 or NPC2 genes. The diagnosis of NP‑C remains challenging due to the non‑spe‑
cific, heterogeneous nature of signs/symptoms. This study assessed the utility of plasma chitotriosidase (ChT) and 
Chemokine (C–C motif ) ligand 18 (CCL18)/pulmonary and activation‑regulated chemokine (PARC) in conjunction 
with the NP‑C suspicion index (NP‑C SI) for guiding confirmatory laboratory testing in patients with suspected NP‑C.
Methods: In a prospective observational cohort study, incorporating a retrospective determination of NP‑C SI scores, 
two different diagnostic approaches were applied in two separate groups of unrelated patients from 51 Spanish 
medical centers (n = 118 in both groups). From Jan 2010 to Apr 2012 (Period 1), patients with ≥2 clinical signs/
symptoms of NP‑C were considered ‘suspected NP‑C’ cases, and NPC1/NPC2 sequencing, plasma chitotriosidase 
(ChT), CCL18/PARC and sphingomyelinase levels were assessed. Based on findings in Period 1, plasma ChT and CCL18/
PARC, and NP‑C SI prediction scores were determined in a second group of patients between May 2012 and Apr 2014 
(Period 2), and NPC1 and NPC2 were sequenced only in those with elevated ChT and/or elevated CCL18/PARC and/
or NP‑C SI ≥70. Filipin staining and 7‑ketocholesterol (7‑KC) measurements were performed in all patients with NP‑C 
gene mutations, where possible.
Results: In total across Periods 1 and 2, 10/236 (4%) patients had a confirmed diagnosis o NP‑C based on gene 
sequencing (5/118 [4.2%] in each Period): all of these patients had two causal NPC1 mutations. Single mutant NPC1 
alleles were detected in 8/236 (3%) patients, overall. Positive filipin staining results comprised three classical and five 
variant biochemical phenotypes. No NPC2 mutations were detected. All patients with NPC1 mutations had high ChT 
activity, high CCL18/PARC concentrations and/or NP‑C SI scores ≥70. Plasma 7‑KC was higher than control cut‑off 
values in all patients with two NPC1 mutations, and in the majority of patients with single mutations. Family studies 
identified three further NP‑C patients.
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Background
Niemann-Pick disease type C (NP-C) is a rare inherited 
lysosomal storage disorder with an estimated incidence 
of 1:120,000 live births [1]. Mutations in either of the two 
genes, NPC1 or NPC2, have been described as the cause 
of the disease [1]. Approximately 95% of patients with a 
genetic diagnosis have NPC1 mutations: NPC1 encodes 
a large membrane glycoprotein with mostly late-endo-
somal localization [2]. Other patients have mutations in 
the NPC2 gene, which encodes a small soluble lysosomal 
protein that binds cholesterol with high affinity [1, 3].
The diagnosis of NP-C remains challenging as neuro-
logical signs of the disease are extremely varied in terms 
of severity and age at onset [1, 4]. In particular, the age 
at onset of neurological manifestations has a major influ-
ence on disease progression and prognosis, and patients 
can be categorized on the basis of early-infantile, late-
infantile, juvenile and adolescent/adult neurological 
onset to aid clinical management and family counselling 
[4]. Generally, patients with very early-onset disease are 
detected and diagnosed based on pronounced visceral 
symptoms such as prolonged neonatal jaundice, fetal 
hydrops and/or ascites [1, 5]. Diagnoses in later-onset 
patients depend more on the recognition of typical neu-
rological signs such as vertical supranuclear gaze palsy 
(VSGP), developmental delay, cerebellar ataxia, and 
gelastic cataplexy, which may or may not be detected 
alongside splenomegaly. However, visceral symptoms can 
appear long before neurological signs and often go unrec-
ognized, particularly in those with adolescent/adult-
onset disease [1, 4].
The NP-C suspicion index (NP-C SI) was developed by 
an international team of experts for the detection of NP-C 
among patients suspected of having the disease, and is 
based on easily assessed patient clinical symptoms and 
medical history [6]. Patients scoring ≥70 on the NP-C SI 
should be considered as possibly having NP-C and should 
undergo further, specific laboratory tests. Scores  <40 on 
the NP-C SI indicate a low likelihood of NP-C [4].
Niemann-Pick disease type C diagnoses can only be 
confirmed using specific laboratory tests [4]. Filipin 
staining in patient skin fibroblast cultures is a sensitive 
and specific test to identify impaired intracellular choles-
terol transport and homeostasis. This test has been con-
sidered the gold standard method for diagnosing NP-C 
because it establishes the biochemical phenotype of the 
disease and provides useful functional evidence of the 
pathogenicity of novel gene mutations [4, 7–10]. How-
ever, recent progress in gene mutation analysis, the lack 
of correlation between some causal mutations and ‘vari-
ant’ filipin staining patterns, and the fact that the filipin 
test is time consuming and expensive, have led to this 
gold standard being challenged [8, 11]. Most patients 
with NP-C (80–85%) show a ‘classical’ pattern of choles-
terol storage featuring numerous, strongly fluorescent 
perinuclear vesicles. However, some patients display a 
‘variant’ biochemical phenotype that features a less dis-
tinct, more variable pattern [9, 10].
The establishment of reliable biomarkers for the pres-
ence and progression of NP-C represents an important 
goal. Chitotriosidase (ChT) is a human plasma chitinase 
enzyme that shows markedly elevated activity in a vari-
ety of lysosomal storage disorders [12, 13], High plasma 
levels reflect gradual intralysosomal accumulation of 
the enzyme in lipid-loaded macrophages, which secrete 
it [14]. Plasma ChT is widely used in Gaucher disease 
(GD) to monitor treatment response to enzyme replace-
ment therapy (ERT) [12]. Ries et al. reported that patients 
with NP-C showed a mean plasma ChT activity of 
856 ± 721 nmol/mL*h compared with 55 ± 35.6 nmol/
mL*h in individuals with miscellaneous other diseases, 
and 13,761  ±  10,348  nmol/mL*h in patients with GD 
[15]. A ChT activity >200 nmol/mL*h is considered path-
ological [15]. However, 3–6% of individuals with Euro-
pean ancestry have the c.1049_1072dup24 polymorphism 
of the ChT gene (CHIT1), which leads to a complete lack 
of ChT activity [16, 17].
Chemokine (C–C motif ) ligand 18 (CCL18)/pulmonary 
and activation-regulated chemokine (PARC) is produced 
mainly by monocytes/macrophages that constitutively 
express it only at low levels in normal circumstances, but 
its production can be up-regulated in these cells by mac-
rophage activators [18]. Plasma CCL18 levels have been 
reported to increase 29-fold in symptomatic GD patients 
[19] leading to its use as a further disease biomarker [20]. 
Pineda et  al. observed that patients with early- or late-
infantile onset NP-C had higher plasma CCL18/PARC 
activities compared with juvenile-onset or asymptomatic 
patients, and proposed CCL18/PARC as an alternative 
marker in NP-C patients with ChT deficiency [20, 21].
Levels of several cholesterol oxidation products (oxys-
terols) have recently been proposed as sensitive and 
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specific markers for NP-C screening and/or diagnosis. 
Increased plasma 7-ketocholesterol (7-KC) levels have 
been reported in NP-C patients and in an NP-C mouse 
model [7, 22]. Further, Porter et  al. have described an 
oxysterol profile specific for NP-C that correlates with 
the age of disease onset as well as disease severity [23].
In the following study, we evaluated whether plasma 
ChT activity and CCL18/PARC concentration might 
complement clinical assessments for the identification of 
patients who should undergo further, specific testing for 
NP-C. We also compared these biomarker analyses with 




Patients from 51 Spanish medical centres specializing in 
neurodegenerative disorders who had two or more symp-
toms typically seen in NP-C were considered as possibly 
having the disease, and were enrolled into this prospec-
tive observational study combined with a retrospective 
determination of NP-C SI scores following reference to 
a questionnaire with a list of symptoms and clinical data 
of interest (see Additional file 1). Patients presenting with 
at least two of the following symptoms were included in 
the study: bipolar disorder; schizophrenia; depression; 
one other clinical symptom. Medical chart data relating 
to demographics, diagnosis, and recorded disease char-
acteristics were obtained from referring physicians.
The study comprised two observation periods, dur-
ing which different diagnostic approaches were fol-
lowed. In Period 1, which ran from January 2010 to April 
2012, patients with two or more clinical NP-C signs and 
symptoms were considered as having ‘suspected NP-C’. 
NPC1/NPC2 sequencing, ChT and sphingomyelinase 
activities, and CCL18/PARC concentration were assessed 
in all patients. If either one or two NPC1 or NPC2 muta-
tions were identified, filipin staining and oxysterol meas-
urements were also performed, where possible. In Period 
2, which ran from May 2012 to April 2014, ChT activity, 
CCL18/PARC concentration and NP-C SI scores were 
analyzed in all patients, and NPC1/NPC2 sequencing 
was performed only in those who had elevated ChT and 
CCL18/PARC values (greater than mean + two standard 
deviations [SD] versus control values), and/or an NP-C SI 
score ≥70. Filipin staining and/or plasma oxysterol meas-
urements were performed, where possible, in all patients 
with either one or two NPC1 or NPC2 mutations.
Genetic analysis
DNA was isolated from EDTA blood samples using 
standard methods. The promoter and 25 exons of NPC1, 
and respective exon–intron boundaries, were ampli-
fied simultaneously in 24 PCR reactions using oligonu-
cleotide primers developed in-house at the University 
of Zaragoza. The promoter, coding regions of the five 
exons of NPC2 and respective exon–intron boundaries 
were amplified in a single multiplex reaction with linker-
tailed primers. Amplification products were joined into 
one DNA fragment using universal external primers, and 
the resulting amplicons were purified using the Illustra™ 
ExoStar™ 1-Step system (GE Healthcare, UK), followed 
by 5′ to 3′ sequencing in an ABI 3500XL DNA analyzer 
(Applied Biosystems, USA).
To analyze splicing variants, total RNA was isolated 
from cultured fibroblasts (1  ×  106 cells/column) using 
the RNeasy Mini Kit (Qiagen, USA), and genomic DNA 
was removed using the RNase-Free DNase Set (Qiagen). 
RNA (200 ng for each reaction) was used for cDNA syn-
thesis with random hexamer primers using RevertAid H 
(Qiagen) minus first strand cDNA synthesis. Two frag-
ments, one from c.227 to c.976 and another from c.1793 
to c.2359, were amplified by PCR, purified using the Illus-
tra™ ExoStar™ 1-Step system (GE Healthcare), followed 
by 5′ to 3′ sequencing in an ABI 3500XL DNA analyzer 
(Applied Biosystems). All primer sequences used for PCR 
are available upon request.
Patients with only one NPC1 mutation were fur-
ther analyzed by Multiplex Ligation-dependent Probe 
Amplification (SALSA® MLPA® P193 NPC1 version A2; 
MRC Holland, Netherlands) in order to find any rear-
rangements, with data normalized versus three healthy 
controls.
A number of software databases (PolyPhen-2 [24], 
SIFT [25] and MutationTaster [26]) were used to evalu-
ate the pathogenicity of newly identified genetic variants 
that implied non-synonymous changes. The effect of var-
iants in potential splicing sites was predicted using Net-
Gene2 and NNSplice by analyzing the structure of donor 
and acceptor sites with a separate neural network rec-
ognizer for each site [27, 28]. Common polymorphisms 
were excluded, and gene variations were compared 
with databases of the National Center for Biotechnol-
ogy Information (NCBI; http://www.ncbi.nlm.nih.gov/), 
Ensembl (http://www.ensembl.org/), the 1000 Genomes 
project (http://www.1000genomes.org/), and the Exome 
Variant Server (http://evs.gs.washington.edu/EVS/). All 
mutations were described according to the latest Human 
Genome Variation Society (HGVS) recommendations 
(http://www.hgvs.org/mutnomen).
Chitotriosidase activity and CCL18/PARC concentration
Plasma for biomarker measurements was separated from 
EDTA blood samples. Plasma ChT activity was measured 
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using the fluorogenic substrate 4MU-chitotrioside (Sigma 
Chemical Co., USA), as described previously [12]. Geno-
typing for the 24-bp insertion in exon 10 of the CHIT1 
gene (c.1049_1072dup24) was performed as described 
by Irun et al. [16]. Given that ChT activity is roughly half 
of normal or zero in patients who are heterozygous and 
homozygous for the c.1049_1072dup24 CHIT1 mutation, 
respectively, ChT levels were multiplied by two in het-
erozygous patients. The concentration of the chemokine 
CCL18/PARC was analyzed by enzyme-linked immuno-
sorbent assay (ELISA; R&D Systems Europe, Ltd, UK) 
as described elsewhere [19]. Mean ±  SD control values 
determined in 36 patients who did not have lysosomal 
disorders were: 46.1 ± 30.2 nmol/mL/h for ChT activity, 
and 52.5 ± 30.3 ng/mL for CCL18/PARC concentration.
NP‑C suspicion index
Individuals  >4  years old were assessed using the NP-C 
SI as described in detail elsewhere (http://www.npc-si.
com) [6]. The NP-C SI was published in 2012, but it was 
considered useful in the context of the current study and 
was therefore applied retrospectively in Period 1 and pro-
spectively in Period 2.
Filipin staining
Normal and NP-C fibroblasts were cultured using stand-
ard laboratory methods, but with some adaptations (see 
Additional file  2). Only homogeneous confluent cell 
monolayers grown over 3–6 passages, and covering an 
area of 25 cm2, were studied. Fluorescent staining of lyso-
somal cholesterol in fibroblast cultures was performed 
based on a well-known cytochemical method in low-den-
sity lipoprotein (LDL)-challenged cells, and perinuclear 
cholesterol accumulation was assessed as described pre-
viously [9].
Oxysterol analysis
The concentration of 7-KC was measured in all patients 
with available plasma samples and at least one identified 
NPC1 mutation. Extraction of 7-KC from plasma sam-
ples was conducted according to the method described 
by Lin et  al. [22], and 7-KC was quantified using liquid 
chromatography-tandem mass spectrometry (LC–MS/
MS) based on a slightly modified version of the method 
described by Baila-Rueda et al. [29]. Briefly, a calibration 
curve for 7-KC showed a correlation coefficient of 0.995, 
with an assay linear range of 2–800  ng/mL. The lower 
limits of detection (LOD) and quantitation were 1 and 
2 ng/mL, respectively. Intra-day and inter-day variations 
were <5 and <11%, respectively. Mean ± SD control val-
ues determined in 36 patients who did not have lysoso-
mal disorders were 15.99 ± 14.67 ng/mL.
Family studies
Genetic analyses were applied in all available first-degree 
relatives of index cases possessing two NP-C gene muta-
tions in order to establish whether mutations were 
located in the same allele or in different alleles, and to 
identify other NP-C patients.
Statistical methods




In total, 236 unrelated patients with suspected NP-C 
were included in Periods 1 and 2 (Fig. 1). All 118 patients 
included during Period 1 underwent NPC1/NPC2 
sequencing, among whom five patients were found to 
be homozygous or compound heterozygotes for NPC1 
mutations (Table 1), and three were found to be carriers 
of single heterozygous NPC1 mutations (Table 2).
In Period 2, 118 patients were assessed for biomark-
ers (ChT and CCL18/PARC). But based on biomarkers 
results, only 43 out of 118 patients in Period 2 underwent 
genetic testing. Five of the 118 patients enrolled during 
Period 2 were homozygous or compound heterozygotes 
for NPC1 mutations (Table  1), and a further five were 
carriers of one NPC1 allele variant (Table  2). Sphingo-
myelinase deficiency was detected in two patients who 
were subsequently diagnosed with Niemann-Pick disease 
type B based on SMPD1 gene mutation analysis. Another 
patient showed acid glucosidase deficiency (with <10% of 
normal activity), and was diagnosed with GD after identi-
fication of two GBA mutations.
ChT and CCL18/PARC analyses
The mean ± SD plasma CCL18/PARC concentration and 
ChT activity in the five patients from Period 1 with an 
identified genetic cause for NP-C were 289 ± 286 ng/mL 
(range 88–788 ng/mL) and 380 ± 374 nmol/mL*h (range 
156–1045  nmol/mL*h), respectively. Patients with one 
mutation had substantially lower values: 185 ± 56.3 ng/
mL (range 123–233 ng/mL) and 110 ± 56.1 nmol/mL*h 
(range 53–167  nmol/mL*h), respectively. Excluding 
patient NPC4B who had no available data, all patients 
with NPC1 mutations showed CCL18/PARC concentra-
tions and/or corrected ChT activities that were at least 
two SDs greater than control values.
In Period 2, 43/118 (36%) patients had CCL18/PARC 
concentrations and/or corrected ChT activities at 
least two SDs greater than control values (i.e., CCL18/
PARC  >115  ng/mL and/or ChT  >150  nmol/mL*h) [16], 
or normal biomarker levels but an NP-C SI score >70. In 
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this Period, 18 patients showed elevated levels of both 
ChT and CCL18/PARC, six only showed elevated ChT 
activity, and 14 had elevated CCL18/PARC concentra-
tions. Five patients had only NP-C SI  ≥70, and 13/118 
subjects from Period 2 had NP-C SI  ≥70. NPC1 and 
NPC2 mutation analyses were therefore conducted in 43 
patients in this group.
Analysis for the c.(1049_1072) dup24 CHIT1 genotype 
identified four and three homozygous patients in Peri-
ods 1 and 2, respectively, and five and 10 heterozygous 
patients in Periods 1 and 2, respectively. The homozygous 
patients were not excluded from the study because it was 
still possible to analyze CCL18/PARC concentration and 
NP-C SI scores.
NP‑C suspicion index analysis
Overall, 79 (33%) of all enrolled patients had an NP-C SI 
risk prediction score  ≥70 following clinical screening, 
17 (7.1%) of whom were children <4 years old. Six out of 
10 of the NP-C patients who had two NPC1 mutations 
had a high suspicion of NP-C (risk prediction score ≥70) 
(Table  1). The remaining patients were either  <4  years 
old or had an NP-C SI  <70. Among patients in the 
single-NPC1 mutation group, of which four were chil-
dren aged <4 years, only one patient had an NP-C SI ≥70 
(Table 2).
Filipin staining
Skin biopsies were performed in all patients who con-
sented to them, and diagnoses of NP-C were con-
firmed based on abnormal filipin staining in these 
cases (Table  1). Six patients with a single NPC1 muta-
tion showed a variant filipin staining pattern, while two 
showed a classical staining pattern (Table 2).
Oxysterol analysis
Plasma 7-KC concentrations were analyzed in 17 NP-C 
patients and 21 relatives. The mean  ±  SD 7-KC level 
among all patients with two NPC1 mutations was 
350.8 ± 221.8 ng/mL (range 103–761 ng/mL), and all of 
these patients had plasma 7-KC concentrations higher 
than the optimal control cut-off value (102.8  ng/mL) in 
our laboratory (Table 3). Among patients with one muta-
tion, the mean ± SD 7-KC concentration was also raised 
(194  ±  265.9  ng/mL [range  <2–761  ng/mL]), although 
only 4/7 of these patients, all of whom had positive 
Fig. 1 Patient flow and diagnosis
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classical or variant filipin staining results, had plasma 
7-KC concentrations higher than the cut-off value.
Clinical manifestations
Clinical manifestations are summarized in Table  4. 
The most prevalent manifestations in patients with a 
confirmed diagnosis of NP-C were neurological signs, 
including: ataxia, VSGP, dementia, dystonia and/or dys-
arthria. Psychiatric signs were the second most frequent 
class of manifestation, and included pre-senile cognitive 
decline/dementia, psychotic symptoms, and depression/
bipolar disorders. Unexplained splenomegaly with or 
without concurrent hepatomegaly were present in 5/10 
patients (50%) with a confirmed diagnosis.
NPC1 mutations
Patients diagnosed with NP-C in this cohort showed wide 
heterogeneity of NPC1 variants. In total, eight new NPC1 
variants were detected: four missense (p.(Thr375Ala), 
p.(Leu846Pro), p.(Arg1173Gly), p.(Arg1274Trp)), 
two different tentative splicing variants at intron 
12 (c.(1947  +  10G  >  A)) and exon 5 (c.(612C  >  T), 
p.(Thr204Thr)), one deletion (c.318_318delC) that produces 
a frameshift change, p.(L107CfsX5), and one rearrange-
ment (c.(280 + ?_c.630 + ?) dup (p.Glu61 + _Asp211 + ?)
dup)) that leads to a duplication of exons 4 and 5. In silico 
analysis with Polyphen2, SIFT and MutationTaster software 
indicated that these changes could affect protein function 
(Table 5). We also found 17 rare NPC1 variants previously 
Table 1 Mutational and biochemical features of NP-C patients with two NPC1 mutations
Mutations were described according to the latest HGVS recommendations (http://www.hgvs.org/mutnomen); ChT chitotriosidase (ChT activity of heterozygous 
individuals [dup24] was multiplied by two). NC not conducted (patient < 4 years old), ND no data available, Neg negative, 7‑KC 7‑ketocholesterol, LOD limit of 
detection (= 2 ng/mL)
Patient ID Variant  
























NPC1A p.(Gln775Pro) [32] p.(Asp1097Asn) [31] 156 188 (Het) 145 ND 260 Adult
NPC2A p.(Arg1059*) [30] p.(Arg1059*) [30] 788 1045 (Neg) NC (<4 y.o.) Classical 650 Early infantile
NPC3A p.(Pro1007Ala) [36] p.(Asn222Ser) [34] 88 266 (Neg) 60 Variant 103 Adult
NPC4A p.(Arg518Trp) [35] p.(Gly992Trp) [36] 151 244 (Neg) 195 ND 213 Adult
NPC5A p.(Trp942Cys) [30] p.(Arg1173Gly) New 266 156 (Het) 95 ND 178 Adult
Period 2
NPC6A p.(Arg372Trp) [30] p.(Thr1036Met) [2] 466 415 (Neg) 20 ND 238 Adult
NPC7A p.(Glu1188 fs*54) [30] p.(Thr375Ala) New 265 75 (Neg) 200 ND 398 Adult
NPC8A p.(Ile1061Thr) [17] p.(Ile1061Thr) [17] 1137 1477 (Neg) NC (<4 y.o.) ND 514 Early infantile
NPC9A p.(Cys177Tyr) [35] p.(Val664Met) [34] 516 614 (Neg) 190 Classical 193 Adult
NPC10A p.(Leu107Cfs*5) [32] p.(Glu61 + ?_
Asp211 + ?)dup
New 1048 812 (Het) NC (<4 y.o.) Classical 761 Early infantile
Table 2 Mutational and biochemical features of ‘NP-C uncertain’ patients with only one NPC1 mutation
Mutations were described according to the latest HGVS recommendations (http://www.hgvs.org/mutnomen); ChT chitotriosidase (ChT activity of heterozygous 
individuals [dup24] multiplied by two), NC not conducted (patient <4 years old), ND no data available, Neg negative, 7‑KC 7‑ketocholesterol, LOD limit of detection 
(=2 ng/mL)
Patient ID Variant allele 1 
amino acid










NPC1B p.(Leu846Pro) New 233 109 (Neg) 55 Variant Negative 134 Adult
NPC2B p.(Phe1221Sfs*20) [30] 123 53 (Neg) 60 Classical Negative 34 Adult
NPC3B p.(Gln775Pro) [32] 198 167 (Neg) 55 Classical Negative <2 Adult
Period 2
NPC4B p.(Arg1274Trp) New ND ND NC (<4 y.o.) Variant Negative ND Early infantile
NPC5B p.(Glu451Lys) [36] 550 771 (Neg) NC (<4 y.o.) Variant Negative 258 Early infantile
NPC6B p.(Asn222Ser) [34] 138 59 (Neg) NC (<4 y.o.) Variant Negative 150 Late infantile
NPC7B p.(Gln775Pro) New 416 132 (Neg) 101 Variant Negative 125 Adult
NPC8B p.(Gln775Pro) [32] 39 24 (Neg) 120 Variant Negative 19 Juvenile
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associated with NP-C. A further 17 common NPC1 vari-
ants or polymorphisms were also observed, including: 
c.(−22A > C), p.(Tyr129Tyr), p.(His215Arg), p.(Pro237Ser), 
p.(Ser322Ser), p.(Asn490Thr), p.(Met642Ile), p.(Ile858Val), 
p.(Asn931Lys), c.(1947 +  10G  >  C), c.(1947 +  14G  >  T), 
c.(2086 + 8G > C), c.(2911 + 28T > C), c.(3246 + 46C > T), 
c.(3591  +  35C  >  T), c.(3754  +  34A  >  G), and 
p.(Arg1266Gln). Five NPC2 polymorphisms were detected 
(p.(Gly52Gly), p.(Ser67Pro), p.(Pro86Leu), p.(Ser121Ala) 
and c.(441  +  437T  >  C)), but no allele mutations were 
identified.
Two variants of uncertain significance were detected 
(c.(1947  +  10G  >  A) and c.(612C  >  T)). Comple-
mentary DNA sequencing was conducted in fibro-
blast DNA obtained from patient NPC10 to better 
classify these two variants, and confirmed the pres-
ence of heterozygous mutations (p.(Leu107CysfsX5) 
and c.(612C > T) [p.Thr204Thr]). We also identified the 
c.(280 + ?_c.630 + ?)dup variant. The c.(1947 + 10G > A) 
mutation was analyzed, and a splicing effect has not been 
observed.
Family studies
Forty-nine relatives were available for genetic analysis, 
and 22 were identified as carriers of at least one NPC1 
mutation. Three relatives were identified as compound 
heterozygotes for NPC1 mutations: p.(Pro1007Ala)-
p.(Asn222Ser); p.(Trp942Cys)-p.(Arg1173Gly); and 
p.(Glu1188  fs*54)-p.(Thr375Ala). Further examination 
of these three individuals revealed clinical symptoms of 
NP-C, and they were subsequently diagnosed with NP-C.
Discussion
Due to the variability of age at onset and presentation in 
NP-C it is crucial to determine which diagnostic strat-
egy might best help identify affected patients among 
suspected cases. We evaluated two different diagnostic 
pathways incorporating two well characterized biomark-
ers that have previously been used to monitor lysosomal 
storage disease progression (ChT activity and CCL18/
PARC concentration) alongside appraisals of clinical 
symptoms and NP-C SI assessments.
The diagnostic approach in Period 1 was to sequence 
all exon and exon–intron boundaries of NPC1 and NPC2 
in patients with suspected NP-C based on the presence 
of two or more typical signs/symptoms. All patients with 
two NPC1 mutations, or a single NPC1 mutation plus 
a positive filipin test, had elevated ChT activity and/or 
CCL18/PARC concentration. Ninety-eight patients with-
out NPC1 mutations did not show elevated ChT activity 
or CCL18/PARC concentration, but retrospective NP-C 
SI assessments showed that 42 of these patients had 
NP-C SI scores  ≥70. Based on findings from Period 1, 
during period 2 we conducted NPC1 and NPC2 sequenc-
ing only in patients with elevated CCL18/PARC concen-
tration and/or ChT activity, or with an NP-C SI ≥70 for 
all individuals  >4  years old. During this second period, 
five patients with homozygous or compound-heterozy-
gous NPC1 mutations were successfully identified. Five 
carrier heterozygote patients with single NPC1 variants 
and positive filipin test findings (classical or variant bio-
chemical phenotypes) were also detected.
We observed the same NP-C detection rate (5/118; 
4.2%) using the criteria of study Period 1 (i.e., NPC1 and 
NPC2 sequencing in all cases of suspected NP-C) as we 
did using the criteria of study Period 2 [i.e., NPC1 and 
NPC2 sequencing only when the ChT activity and/or 
CCL18/PARC concentration were elevated and/or NP-C 
SI was ≥70; 5/118 cases (4.2%)]. These findings suggest 
that the measurement of one or both of plasma ChT 
activity and CCL18 concentration in conjunction with 
Table 3 Patient demographics and  diagnostic features 
among all study patients
All patients, including those from both Periods 1 and 2. Data expressed as 
mean ± SD, median and range (minimum–maximum). Normal biomarker values 
calculated in 36 patients without lysosomal disorders were: 46.1 ± 30.2 nmol/
mL/h for ChT activity; 52.5 ± 30.3 ng/mL for CCL18/PARC concentration; and 
15.99 ± 14.67 ng/mL for 7‑KC concentration. ND no data available
NP‑C positive 











Mean ± SD 28 ± 21 28 ± 28 44 ± 22
Median (range) 35 (1.4–62) 21 (0.8–68) 46 (0.03–83)
Gender (n)
Male 4 6 126
Female 6 2 92
NP‑C SI  (points)
Mean ± SD 129 ± 72.1 78.2 ± 27.1 58.9 ± 39.2
Median (range) 145 (20–200) 69.1 (55–120) 55 (5–245)
ChT activity
(nmol/mL/h)
Mean ± SD 553 ± 479 187 ± 262 122 ± 423
Median (range) 255 (75–1477) 109 (24–771) 53 (11–5149)
CCL18 conc. (ng/mL)
Mean ± SD 481 ± 370 242 ± 179 95 ± 178
Median (range) 266 (88–1137) 198 (39–550) (11–1513)
7‑KC
(ng/mL)
Mean ± SD 351 ± 222 103 ± 91.20 ND
Median (range) 249 (103–761) 198 (<2–761)
Filipin staining (n)
Classical 3 2 ND
Variant 1 6
No data 6 0
Page 8 of 11De Castro‑Orós et al. J Transl Med  (2017) 15:43 
assessment of NP-C SI score in patients with suspected 
NP-C allows better targeting of in-depth confirmatory 
laboratory tests. A reduced number of patients were 
referred for confirmatory molecular-genetic testing, ena-
bling decreases in both the time and costs associated 
with diagnosing NP-C.
Considering findings from both study periods together, 
although the majority of NP-C patients with two NPC1 
mutations had elevated levels of both ChT and CCL18/
PARC, two subjects had a clear genetic diagnosis of NP-C 
but showed raised levels of only one of these biomarkers.
Across the two periods in the current study, we iden-
tified a total of six novel NPC1 variants and 17 NPC1 
mutations that have been described previously [2, 17, 
30–36]. No causal NPC2 mutations were detected. Eight 
of the patients examined in this study only had a single 
NPC1 mutation, and it is considered highly likely that all 
of these patients are true cases of NP-C based on their 
clinical presentation, filipin staining findings, and plasma 
ChT, CCL18 and 7-KC values. It is possible that these 
patients also had a second point mutation that was not 
detectable with our sequencing and MLPA methodology. 
Alternatively, these mutations could have resulted from 
whole-gene deletions, intron sequence variants or muta-
tions in other genes that could modify intra-lysosomal 
cholesterol transport. Full-gene sequencing is possible 
using next-generation methods, but this is likely to iden-
tify variants that are difficult to interpret.
We observed that patients with homozygous or com-
pound-heterozygous NPC1 mutations, as well as carri-
ers of single NPC1 mutations, had elevated ChT activity 
and CCL18/PARC concentration, although levels of these 
biomarkers were higher in NP-C positive patients than 
in ‘NP-C uncertain’ individuals. The existence of CHIT1 
polymorphisms associated with reduced ChT activity lim-
its the usefulness of ChT as a biomarker in some patients 
[16]. Nonetheless, the combined analysis of both ChT and 
CCL18/PARC levels allowed the identification of four addi-
tional patients with lysosomal storage diseases: three patients 
with Niemann-Pick disease type B and one with GD.
The NP-C SI, which was developed in 2012, was applied 
retrospectively to individuals assessed during Period 1 and 
prospectively in those assessed during Period 2 in order to 
Table 4 Clinical disease characteristics of all patients









Neurological symptoms, n (%)
Vertical supranuclear gaze palsy (VSGP) 3 (30%) 3 (37.5%) 58 (26.6%)
Gelastic cataplexy 0 (0%) 0 (0%) 7 (3.2%)
Ataxia, clumsiness or frequent falls 5 (50%) 3 (37.5%) 89 (40.8%)
Dysarthria and/or dysphagia 2 (20%) 3 (37.5%) 31 ((14.2%)
Dystonia 1 (10%) 1 (12.5%) 55 (25.2%)
Psychiatric symptoms present, n (%)
Pre‑senile cognitive decline or dementia 2 (20%) 1 (12.5%) 76 (34.9%)
Psychotic symptoms (schizophrenia) 1 (10%) 0 (0%) 19 (8.7%)
Depression 3 (30%) 2 (25%) 49 (22.5%)
Bipolar disorders 1 (10%) 1 (12.5%) 12 (5.5%)
Visceral symptoms, n (%)
Unexplained neonatal jaundice or cholestasis 1 (10%) 2 (25%) 12 (5.5%)
Unexplained splenomegaly ± hepatomegaly 6 (60%) 3 (37.5%) 15 (6.9%)
Hydrops fetalis or fetal ascites 0 (0%) 0 (0%) 1 (0.5%)
Table 5 In silico mutation predictions
PolyPhen‑2 score ranges from 0 to 1, with mutations qualitatively appraised 
as PrD (probably damaging), PoD (possibly damaging), or B (benign). 
MutationTaster analyses the probability that a variant will be disease‑causing or 
is a polymorphism. SIFT scores range from 0 to 1: the amino acid substitution is 
predicted as damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05. 
NA not possible to analyze
Mutation PolyPhen‑2 SIFT Mutation taster
p.(Leu107CfsX5) NA NA Disease‑causing
p.(Thr375Ala) PrD (0.997) Damaging (0.010) Disease‑causing
p.(Leu846Pro) PrD (0.995) Damaging (0.001) Disease‑causing
p.(Arg1173Gly) PrD (0.999) Damaging (0.007) Disease‑causing
p.(Arg1274Trp) PrD (0.986) Damaging (0.004) Disease‑causing
p.(Thr204Thr) NA Tolerated (0.703) Disease‑causing
c.(1947 + 10G > A) NA NA Polymorphism
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gain a complete set of diagnostic data. This clinical tool 
has shown promise in aiding the diagnosis of NP-C in 
previous studies [6]. However, we observed high predic-
tion scores (≥70) in 79 of all included patients  >4  years 
old in the current cohort, in which only six patients had 
a confirmed diagnosis of NP-C. While several patients 
in this cohort had high NP-C SI scores as well as clinical 
signs associated with NP-C (VSGP and splenomegaly), 
genetic analyses did not reveal any NPC1 or NPC2 muta-
tions. Conversely, the NP-C SI cut-off value of 70, recom-
mended as an indicator for additional diagnostic tests, 
could have led to non-detection of NP-C in two patients 
who had scores of 60 and 20. The measurement of plasma 
ChT activity and CCL18/PARC concentration as well 
as NP-C SI assessments allowed us to confirm a total of 
eight NP-C diagnoses. In addition, two patients in whom 
the NP-C SI was not applicable due to their age (<4 years) 
were detected based on biomarker measurements alone.
It should be borne in mind that elevations in CCL18/
PARC concentration are not exclusively caused by lyso-
somal disorders. CCL18/PARC is a circulating chemokine 
that plays a role in injury healing, physiological homing 
of mononuclear blood cells, and inflammatory responses 
[37]. Indeed, some studies have indicated that CCL18/
PARC is expressed in atherosclerotic plaques, and repre-
sents an independent risk predictor of short-term mor-
tality in patients with acute coronary syndromes [38]. 
The lack of correlation between CCL18/PARC levels and 
NP-C SI scores in this study might therefore be due to the 
presence of other concomitant pathologies such as cardio-
vascular disease, which are not considered in the NP-C SI.
The filipin test was performed in as many patients as 
possible in this cohort, and all tested patients with one 
or two NPC1 mutations showed a classical or variant 
filipin staining pattern, respectively. However, it is inter-
esting to note that not all carriers of single NPC1 muta-
tions who had a positive filipin result exhibited elevated 
plasma 7-KC concentrations, whereas all patients with 
two NPC1 mutations had 7-KC levels above the con-
trol cut-off value in our laboratory. It is also notable that 
family studies addressing ChT/CCL18/7-KC biomark-
ers in conjunction with the NP-C SI, filipin testing and 
subsequent gene sequencing led to the identification of a 
further three NP-C patients, and enabled the validation 
of two new causal NPC1 variants (p.(Arg1173Gly) and 
p.(Thr375Ala)).
This investigation has several limitations and 
strengths that should be taken into account in inter-
preting the reported findings. Although the inclusion 
of patients with two typical NP-C symptoms might 
be considered a bias for having a high NP-C SI score, 
it should be noted that this study was started in 2010, 
and the symptoms required for inclusion in this work 
were specified before the NP-C SI was developed and 
published in 2012 [6]. Such a bias was therefore not 
possible. Secondly, we did not sequence all individu-
als with suspected NP-C who had plasma ChT activ-
ity or CCL18/PARC concentration less than the mean 
control value (plus two SDs). However, we did conduct 
NP-C gene sequencing and MLPA in all individuals 
with an NP-C SI ≥70 or who were <4 years old. Thirdly, 
the sequencing techniques that we employed only cov-
ered the coding regions of the NPC1 and NPC2 genes 
and their intron–exon boundaries, and therefore might 
not have detected regulatory and deep intronic splicing 
mutations. It is also possible that some novel mutant 
NP-C gene alleles might not yet have been character-
ized, and therefore may be present (but go undetected) 
among ‘NP-C uncertain’ or even ‘NP-C negative’ indi-
viduals. Finally, the genetic diagnosis of NP-C requires 
the identification of clearly pathogenic mutations, while 
many families have ‘private’ sequence variants that have 
not yet been reported/published. While in silico pro-
tein and splicing prediction tools can be employed to 
assist in assigning pathogenicity to sequence variants 
resulting from missense or intronic changes, decisions 
regarding the pathogenicity of novel, private mutations 
are generally very difficult to make.
Conclusion
We conclude that plasma ChT activity and CCL18/PARC 
concentration measurements in patients with suspected 
NP-C based on their clinical symptomatology can help 
pave the way to conducting specific, confirmatory labo-
ratory tests. This approach can be very useful for labo-
ratories that do not have mass spectrometry facilities 
and therefore they cannot use other NP-C biomarkers 
such lyso-sphingomyelin-509 or bile acids. Patients with 
a plasma ChT activity and/or plasma CCL18/PARC con-
centration greater than two SDs beyond control values 
and an NP-C SI score  ≥70 should undergo NPC1 and 
NPC2 gene sequencing as standard. In addition, identifi-
cation of two pathogenic NP-C gene mutations that seg-
regate in the family should be considered sufficient for at 
least an initial diagnosis.
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